Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study is health economic analysis of medicinal treatment options for moderate-to-severe
psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes
will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for
moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various
different sources, including summary of product characteristics (SPCs) and the German S3
guideline on psoriasis care, health care utilization data and official statistics.
The study aims to investigate the comparative cost-effectiveness of biologic and conventional
systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe
plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled
(Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as
well as indirect cost will be considered.